Home/Pipeline/PHST002

PHST002

Oncology

IND EnablingActive

Key Facts

Indication

Oncology

Phase

IND Enabling

Status

Active

Company

Pheast Therapeutics

About Pheast Therapeutics

Pheast Therapeutics is a private, preclinical-stage biotech founded in 2020, focused on discovering and developing innate immune checkpoint inhibitors. Its core technology platform identifies novel 'don't eat me' signals, like CD24, to unleash macrophages against cancers resistant to existing immunotherapies. The company has initiated a Phase 1 trial for its lead anti-CD24 antibody, PHST001, and is backed by a $76M Series A round. Pheast aims to create next-generation therapies for patients with hard-to-treat solid tumors.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active